C5 and age-related macular degeneration: Furthermore, AMD-associated complement factors-C5 [67], cytokines-NAMP [68] were reduced after BAY651942 treatment, supporting the efficacy of BAY651942 as a potential therapeutic molecule to reduce RPE abnormalities and dysfunction in AMD.